Effects of cannabidiol in animal models predictive of antipsychotic activity

Zuardi, A. W.; Antunes Rodrigues, J.; Cunha, J. M.

doi:10.1007/bf02244189

Cited by 191Cannabis and Cannabinoid ResearchSchizophrenia research and treatmentPsychedelics and Drug Studies

Effects of cannabidiol in animal models predictive of antipsychotic activity

Zuardi, A. W., Antunes Rodrigues, J., Cunha, J. M.·1991·Psychopharmacology

DOI 10.1007/bf02244189

Open this paper in CoChat — free account

Abstract

The effects of cannabidiol (CBD) were compared to those produced by haloperidol in rats submitted to experimental models predictive of antipsychotic activity. Several doses of CBD (15-480 mg/kg) and haloperidol (0.062-1.0 mg/kg) were tested in each model. First, CBD increased the effective doses 50% (or) ED50 of apomorphine for induction of the sniffing and biting stereotyped behaviors. In addition, both CBD and haloperidol reduced the occurrence of stereotyped biting induced by apomorphine (6.4 mg/kg), increased plasma prolactin levels and produced palpebral ptosis, as compared to control solutions. However, CBD did not induce catalepsy even at the highest doses, in contrast to haloperidol. Such a pharmacological profile is compatible with that of an "atypical" antipsychotic agent, though the mechanism of action is uncertain and may not be identical to that of the dopamine antagonists.

Integrity signals

Registry

Crossref · 10.1007/bf02244189

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

CBD could have an atypical antipsychotic profile.
“These effects were similar to those of clozapine, suggesting that CBD could have an atypical antipsychotic profile (65).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [65]
CBD only increased prolactin levels at high doses (greater than 120 mg/kg).
“Moreover, CBD only increased prolactin levels at high doses (greater than 120 mg/kg, Table 2).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [65]
CBD did not induce catalepsy, a motor impairment associated with antipsychotic extrapyramidal side effects in humans.
“As opposed to the latter, however, CBD did not induce catalepsy, a motor impairment associated with antipsychotic extrapyramidal side effects in humans.”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [65]

Nonparametric Statistics for the Behavioral Sciences
Guitton, H., & Siegel, S. (1958) · Revue économique · doi:10.2307/3498751 · Cited by 35,281 · see citing works
Arzneimittelforschung
Miletzki, B., & Gleiter, C. H. (2005) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-005-1024-7 · Cited by 9,401 · see citing works
Nonparametric statistics for the behavioral sciences
McGinn, L. C. (1957) · Journal of the Franklin Institute · doi:10.1016/0016-0032(57)90766-4 · Cited by 7,284 · see citing works
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,117 · see citing works
Nonparametric Statistical Methods.
Moore, D. S., Hollander, M., & Wolfe, D. A. (1974) · Journal of the American Statistical Association · doi:10.2307/2285701 · Cited by 2,855 · see citing works
Cannabinoid receptor localization in brain.
Herkenham, M., Lynn, A. B., Little, M. D., Johnson, M. R., Melvin, L. S., de Costa, B. R., & Rice, K. C. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.5.1932 · Cited by 2,321 · see citing works
Tables for Convenient Calculation of Median-Effective Dose (LD 50 or ED 50 ) and Instructions in Their Use
Weil, C. S. (1952) · Biometrics · doi:10.2307/3001557 · Cited by 1,061 · see citing works
Role of brain monoamines and histamine in regulation of anterior pituitary secretion.
Weiner, R. I., & Ganong, W. F. (1978) · Physiological Reviews · doi:10.1152/physrev.1978.58.4.905 · Cited by 701 · see citing works
Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjects
Zuardi, A. W., Shirakawa, I., Finkelfarb, E., & Karniol, I. G. (1982) · Psychopharmacology · doi:10.1007/bf00432554 · Cited by 608 · see citing works
Self-citation
Radioimmunoassay for Rat Prolactin
NISWENDER, G. D., Chen, C. L., MIDGLEY, A. R., et al. (1969) · Experimental Biology and Medicine · doi:10.3181/00379727-130-33657 · Cited by 360 · see citing works
IS IT POSSIBLE TO PREDICT THE CLINICAL EFFECTS OF NEUROLEPTIC DRUGS (MAJOR TRANQUILLIZERS) FROM ANIMAL DATA?I. "NEUROLEPTIC ACTIVITY SPECTRA" FOR RATS.
Janssen, P. A., Cj, N., & Schellekens, K. H. L. (1965) · PubMed · Cited by 348 · see citing works
Current Developments in Psychopharmacology
Sullivan, J. L. (1978) · Psychosomatics · doi:10.1016/s0033-3182(78)71012-1 · Cited by 264 · see citing works
The Effects of Acute Stress on the Secretion of LH, FSH, Prolactin and GH in the Normal Male Rat, with Comments on Their Statistical Evaluation
Krulich, L., Hefco, E., Illner, P., & Read, C. B. (2008) · Neuroendocrinology · doi:10.1159/000122576 · Cited by 262 · see citing works
Cellular effects of cannabinoids.
Martin, B. R. (1986) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06860-7 · Cited by 256 · see citing works
Pharmacological interaction between cannabidiol and ?9-tetrahydrocannabinol
Karniol, I. G., & Carlini, E. A. (1973) · Psychopharmacology · doi:10.1007/bf00428793 · Cited by 182 · see citing works
CANNABIS-ASSOCIATED PSYCHOSIS WITH HYPOMANIC FEATURES
Rottanburg, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91270-3 · Cited by 179 · see citing works
Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine
Costall, B., & Naylor, R. J. (1975) · Psychopharmacology · doi:10.1007/bf00437617 · Cited by 146 · see citing works
Is it possible to predict the clinical effects of neuroleptic drugs (major tranquillizers) from animal data? IV. An improved experimental design for measuring the inhibitory effects of neuroleptic drugs on amphetamine-or apomorphine-induced "Cheroing" and "agitation" in rats.
Janssen, P. A. J., Niemegeers, C. J. E., Schellekens, K. H. L., & Lenaerts, F. M. (1967) · PubMed · Cited by 134 · see citing works
Interactions ofΔ 11-tetrahydrocannabinol with cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentographywith cannabinol and cannabidiol following oral administration in man. Assay of cannabinol and cannabidiol by mass fragmentography
Agurell, S., Carlsson, S., Lindgren, J. E., Ohlsson, A., Gillespie, H., & Hollister, L. (1981) · Experientia · doi:10.1007/bf02085029 · Cited by 129 · see citing works
Antipsychotic drugs stimulate prolactin release
Clemens, J. A., Smalstig, E. B., & Sawyer, B. D. (1974) · Psychopharmacology · doi:10.1007/bf00421361 · Cited by 122 · see citing works
Effect of cannabidiol and of other Cannabis sativa compounds on hippocampal seizure discharges
Izquierdo, I., Orsingher, O. A., & Berardi, A. C. (1973) · Psychopharmacology · doi:10.1007/bf00413961 · Cited by 110 · see citing works
A metabolic interaction in vivo between cannabidiol and Δ1‐tetrahydrocannabinol
Jones, G., & Pertwee, R. G. (1972) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1972.tb08092.x · Cited by 96 · see citing works
Pharmacological interaction between cannabinol and ?9-tetrahydrocannabinol
Takahashi, R. N., & Karniol, I. G. (1975) · Psychopharmacology · doi:10.1007/bf00428937 · Cited by 96 · see citing works
Hypnoticlike effects of cannabidiol in the rat
Monti, J. M. (1977) · Psychopharmacology · doi:10.1007/bf00497858 · Cited by 84 · see citing works
A behavioural and biochemical comparison of dopamine receptor blockade produced by haloperidol with that produced by substituted benzamide drugs
Jenner, P. G., Clow, A., Reavill, C. A., Theodorou, A., & MARSDEN, C. D. (1978) · Life Sciences · doi:10.1016/0024-3205(78)90032-2 · Cited by 78 · see citing works
gamma-Aminobutyric acid (GABA) receptor stimulation. IV. Effect of progabide (SL 76002) and other GABAergic agents on acetylcholine turnover in rat brain areas.
Scatton, B., & Bartholini, G. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33002-8 · Cited by 73 · see citing works
Modification of ?9-THC-actions by cannabinol and cannabidiol in the rat
Fernandes, M. S., Schabarek, A., Coper, H., & Hill, R. (1974) · Psychopharmacology · doi:10.1007/bf00429130 · Cited by 72 · see citing works
Comparison of the effects of substituted benzamides and standard neuroleptics on the binding of 3H-spiroperidol in the rat pituitary and striatum with effects on rat prolactin secretion
Meltzer, H. Y., So, R., Miller, R. J., et al. (1979) · Life Sciences · doi:10.1016/0024-3205(79)90551-4 · Cited by 69 · see citing works
Symposium on: Receptors of dopamine antagonists: New biochemical approaches
Leysen, J. E., & Laduron, P. M. (1978) · Life Sciences · doi:10.1016/0024-3205(78)90145-5 · Cited by 59 · see citing works
High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5'-trimethylammonium delta 8-tetrahydrocannabinol.
Nye, J. S., Seltzman, H. H., Pitt, C. G., & Snyder, S. H. (1985) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)23705-3 · Cited by 54 · see citing works
SEDATIVE ACTIVITY OF CANNABIS IN RELATION TO ITS Δ‘‐ trans ‐TETRAHYDROCANNABINOL AND CANNABIDIOL CONTENT
PICKENS, J. T. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb09145.x · Cited by 48 · see citing works
Antagonism by sulpiride of three apomorphine-induced effects in rodents
Puech, A. J., Simon, P., & Boissier, J. R. (1976) · European Journal of Pharmacology · doi:10.1016/0014-2999(76)90098-4 · Cited by 45 · see citing works
Gabaergic mediation in the inhibition of hippocampal acetylcholine turnover rate elicited by Δ9-tetrahydrocannabinol
Revuelta, A. (1979) · Neuropharmacology · doi:10.1016/0028-3908(79)90095-9 · Cited by 43 · see citing works
Mechanisms Subserving the Stimulatory and Inhibitory Components of γ-Aminobutyric Acid-ergic Control of Prolactin Secretion in the Rat*
Casanueva, F. F., Apud, J. A., Locatelli, V., et al. (1981) · Endocrinology · doi:10.1210/endo-109-2-567 · Cited by 41 · see citing works
Ocular hypotension, ocular toxicity, and neurotoxicity in response to marihuana extract and cannabidiol
Colasanti, B. K., Brown, R. E., & Craig, C. R. (1984) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(84)90202-7 · Cited by 39 · see citing works
The role of 5-hydroxytryptamine in dopamine-dependent stereotyped behaviour
Carter, C. J. (1981) · Neuropharmacology · doi:10.1016/0028-3908(81)90131-3 · Cited by 38 · see citing works
THE ORAL ACTIVITY OF Δ′‐TETRAHYDROCANNABINOL AND ITS DEPENDENCE ON PROSTAGLANDIN E2
Fairbairn, J. W., & PICKENS, J. T. (1979) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1979.tb08691.x · Cited by 37 · see citing works
Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats.
Zuardi, A. W., Teixeira, N. A. A., & Karniol, I. G. (1984) · PubMed · Cited by 36 · see citing works
Self-citation
Influence of gamma-butyrolactone on behavior due to dopaminergic drugs
Dougherty, G. G., & Ellinwood, E. H. (1983) · Physiology & Behavior · doi:10.1016/0031-9384(83)90228-7 · Cited by 19 · see citing works
Some Structural Requirements for Inhibition of High-Affinity Synaptosomal Serotonin Uptake by Cannabinoids
Johnson, K. M., Dewey, W. L., & Harris, L. S. (1976) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)10748-7 · Cited by 16 · see citing works
The effects of some atypical neuroleptics on apomorphine-induced behaviors as a measure of their relative potencies in blocking presynaptic versus postsynaptic dopamine receptors
Robertson, A., & MacDonald, C. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90499-5 · Cited by 14 · see citing works
Use of the intracerebral injection technique to elucidate mechanisms of apomorphine climbing and its antagonism in the mouse
Costall, B., Naylor, R. J., & Nohria, V. (1981) · Psychopharmacology · doi:10.1007/bf00431110 · Cited by 12 · see citing works
Preclinical Psychopharmacology
Eichelman, B. S. (1985) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198510000-00014 · Cited by 11 · see citing works
Acao de canabinoides em convulsoes induzidas pelo acido 3-mercaptopropionico
Benedito, M. A. C., & Leite, J. R. D. S. A. (1981) · Cited by 1 · see citing works

Flagged first, then by citations

Sorted by citations

The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis
D'Souza, D. C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.-T., Braley, G., Gueorguieva, R., & Krystal, J. H. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300496 · Cited by 1,024 · see citing works
Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction
D’Souza, D. C., Abi-Saab, W. M., Madonick, S., Forselius-Bielen, K., Doersch, A., Braley, G., Gueorguieva, R., Cooper, T. B., & Krystal, J. H. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.006 · Cited by 617 · see citing works
Safety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · see citing works
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report
Crippa, J. A. S., Derenusson, G. N., Ferrari, T. B., Wichert-Ana, L., Duran, F. L., Martin-Santos, R., Simões, M. V., Bhattacharyya, S., Fusar-Poli, P., Atakan, Z., et al. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110379283 · Cited by 535 · see citing works
Self-citation
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders
Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., & Guimarães, F. S. (2012) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2011.0389 · Cited by 475 · see citing works
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · see citing works
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: An exploratory double-blind trial
Chagas, M. H. N., Zuardi, A. W., Tumas, V., Pena-Pereira, M. A., Sobreira, E. T., Bergamaschi, M. M., dos Santos, A. C., Teixeira, A. L., Hallak, J. E., & Crippa, J. A. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550355 · Cited by 365 · see citing works
Self-citation
Cannabis and adolescent brain development.
Lubman, D. I., Cheetham, A., & Yücel, M. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.009 · Cited by 360 · see citing works
Cannabidiol for the treatment of psychosis in Parkinson's disease
Zuardi, A., Crippa, J., Hallak, J., Pinto, J., Chagas, M., Rodrigues, G., Dursun, S., & Tumas, V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881108096519 · Cited by 355 · see citing works
Self-citation
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308 · see citing works
Self-citation
Effects of cannabidiol (CBD) on regional cerebral blood flow
Crippa, J. A. D. S., Zuardi, A. W., Garrido, G. E. J., Wichert-Ana, L., Guarnieri, R., Ferrari, L., Azevedo-Marques, P. M., Hallak, J. E. C., McGuire, P. K., & Busatto, G. F. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300340 · Cited by 307 · see citing works
Self-citation
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders
García-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306 · see citing works
Cannabinoids in Clinical Practice
Williamson, E. M., & Evans, F. J. (2000) · Drugs · doi:10.2165/00003495-200060060-00005 · Cited by 283 · see citing works
5‐HT<sub>1A</sub>receptors are involved in the cannabidiol‐induced attenuation of behavioural and cardiovascular responses to acute restraint stress in rats
Resstel, L. B. M., Tavares, R. F., Lisboa, S. F. S., Joca, S. R. L., Corrêa, F. M. A., & Guimarães, F. S. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00046.x · Cited by 283 · see citing works
A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation
Waldo Zuardi, A., Alexandre S. Crippa, J., E.C. Hallak, J., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., K. McGuire, P., & Silveira Guimaraes, F. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802884681 · Cited by 222 · see citing works
Cannabis and psychiatric disorders: it is not only addiction
Leweke, F. M., & Koethe, D. (2008) · Addiction Biology · doi:10.1111/j.1369-1600.2008.00106.x · Cited by 213 · see citing works
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test
Moreira, F. A., Aguiar, D. C., & Guimarães, F. S. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2006.06.004 · Cited by 207 · see citing works
Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
Moreira, F. A., & Guimarães, F. S. (2005) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2005.02.040 · Cited by 206 · see citing works
Cannabidiol monotherapy for treatment-resistant schizophrenia
Zuardi, A. W., Hallak, J. E. C., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., & Crippa, J. A. S. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106060967 · Cited by 192 · see citing works
Self-citation
Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats
Resstel, L. B. M., Joca, S. R. L., Moreira, F. A., Corrêa, F. M. A., & Guimarães, F. S. (2006) · Behavioural Brain Research · doi:10.1016/j.bbr.2006.05.016 · Cited by 182 · see citing works
Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders
Campos, A. C., Fogaça, M. V., Scarante, F. F., Joca, S. R. L., Sales, A. J., Gomes, F. V., Sonego, A. B., Rodrigues, N. S., Galve-Roperh, I., & Guimarães, F. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00269 · Cited by 175 · see citing works
Antidepressant-like effect of cannabidiol injection into the ventral medial prefrontal cortex-Possible involvement of 5-HT1A and CB1 receptors
Sartim, A. G., Guimarães, F. S., & Joca, S. R. L. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.01.033 · Cited by 156 · see citing works
Involvement of the prelimbic prefrontal cortex on cannabidiol-induced attenuation of contextual conditioned fear in rats
Lemos, J. I., Resstel, L. B., & Guimarães, F. S. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.09.045 · Cited by 146 · see citing works
Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice
Schiavon, A. P., Bonato, J. M., Milani, H., Guimarães, F. S., & Weffort de Oliveira, R. M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.06.017 · Cited by 135 · see citing works
Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors
Soares, V. D. P., Campos, A. C., Bortoli, V. C. D., Zangrossi, H., Guimarães, F. S., & Zuardi, A. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.05.004 · Cited by 112 · see citing works
Self-citation
Cannabidiol attenuates sensorimotor gating disruption and molecular changes induced by chronic antagonism of NMDA receptors in mice
Gomes, F. V., Issy, A. C., Ferreira, F. R., Viveros, M.-P., Del Bel, E. A., & Guimarães, F. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu041 · Cited by 89 · see citing works
Cannabidiol effects in the prepulse inhibition disruption induced by amphetamine
Pedrazzi, J. F. C., Issy, A. C., Gomes, F. V., Guimarães, F. S., & Del-Bel, E. A. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3945-7 · Cited by 76 · see citing works
Effects of Adolescent THC Exposure on the Prefrontal GABAergic System: Implications for Schizophrenia-Related Psychopathology
Renard, J., Rushlow, W. J., & Laviolette, S. R. (2018) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2018.00281 · Cited by 62 · see citing works

Authors: Zuardi, A. W., Antunes Rodrigues, J., & Cunha, J. M.
Affiliations: Universidade Federal de Uberlândia (BR)
ORCID: Zuardi, A. W.
Venue: Psychopharmacology
Publisher: Springer Science and Business Media LLC
Published: 1991-06
Volume: 104
Issue: 2
Pages: 260-264
ISSN: 0033-3158 (ISSN-L)
1432-2072
DOI: 10.1007/bf02244189
OpenAlex: W2015650006
Cited by: 191
References: 44
Citations by year: 2025: 2 · 2024: 11 · 2023: 7 · 2022: 9 · 2021: 11 · 2020: 14 · 2019: 9 · 2018: 14 · 2017: 10 · 2016: 13 · 2015: 9 · 2014: 6 · 2013: 9 · 2012: 9
FWCI: 0.41
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords: cannabidiol, haloperidol, antipsychotic activity, stereotypy, apomorphine, catalepsy, prolactin, palpebral ptosis, atypical antipsychotics, dopamine antagonists, animal models of psychosis
MeSH terms: Animals, Apomorphine, Blepharoptosis, Cannabidiol, Catalepsy, Male, Models, Psychological, Prolactin, Rats, Inbred Strains, Stereotyped Behavior, Antipsychotic Agents, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effects of cannabidiol in animal models predictive of antipsychotic activity

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Cites

Cited by

Related

Record

About these checks